AstraZeneca (AZN) Stock: Company Halts Phase III Lung Cancer Trial After Data Fails to Hit Targets

TLDR

• AstraZeneca is discontinuing its Phase III eVOLVE-Lung02 trial testing volrustomig plus chemotherapy in metastatic non-small cell lung cancer patients
• An independent data monitoring committee found the combination was unlikely to meet its primary endpoints in PD-L1 negative patients
• The trial enrolled 895 patients across 25 countries before being halted
• This adds to a string of pipeline setbacks this year, including the Wainua heart disease trial failure
• AstraZeneca is standing by its $80 billion annual revenue target for 2030, with other volrustomig trials continuing

AstraZeneca has discontinued its late-stage eVOLVE-Lung02 trial, which was testing the drug volrustomig combined with chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC).

🚨 ASTRAZENECA $AZN ENDS PHASE III LUNG CANCER TRIAL — BUT SHARES RISE ~1.9%

AstraZeneca is discontinuing its eVolve-Lung02 Phase III trial of volrustomig + chemotherapy in metastatic non-small-cell lung cancer.

🔹 Independent monitors concluded the treatment was unlikely to… pic.twitter.com/VyAaNtmhsb

… Continue reading the full article at the original source below.